PTX3 and metabolic dysfunction-associated steatohepatitis: According to some studies, PTX-3 can be used as an inflammatory marker for the prognosis of patients with hepatic cirrhosis [30]; serum PTX-3 expression markedly increases in adult NASH patients; thus, PTX-3 can be used as a biomarker for the differential diagnosis of NASH and help evaluate the severity of liver fibrosis in patients with NASH [12, 31].